I-Acute Lymphoblastic Leukemia (T-ALL)-10

Umfana oneminyaka engu-13 ubudala ogama lakhe linguYangyang wasePanzhihua, eSifundazweni saseSichuan, wahlinzwa i-CAR-T kwalandela ukufakelwa i-brid.

UYangyang waqala waba "nemivimbo esakazekile emzimbeni wonke ehambisana nokukhathala" ngo-Ephreli 12, 2021. Watholakala ene-acute lymphoblastic leukemia (i-T-cell subtype) ene-intracranial hemorrhage kanye nokutheleleka kwamaphaphu okuqinisekiswe ukuhlolwa kwe-bone marrow MICM esibhedlela esikhulu eChongqing. Wenziwa imijikelezo emithathu ye-chemotherapy kwesinye isibhedlela, kodwa i-bone marrow ayizange isabele. Ekuqaleni kukaJuni, waba nobuthakathaka kuzo zombili izitho zomzimba ezingezansi futhi wayengakwazi ukuhamba.

Ngomhlaka-1 kuJulayi 2021, uYangyang wangeniswa eSigabeni sethu se-Hematology Ward 2. Wabhalisa esivivinyweni somtholampilo se-CD7 CAR-T ngomhlaka-8 kuJulayi futhi wathola i-autologous CD7 CAR-T cell infusion ngomhlaka-26 kuJulayi ukuze athole i-immunotherapy. Ezinsukwini eziyishumi nesithupha ngemuva kokufakwa, i-bone marrow morphology yabonisa ukuxolelwa, kanti i-flow cytometry yabonisa ama-lymphoblast e-T angakavuthwa asolisayo angu-0.07%. Ngemva kokwelashwa ngokomzimba, waphinde wakwazi ukuhamba ngokuzimela. Ngosuku lwama-31 ngemuva kokufakwa, i-bone marrow yakhe yathola ukuxolelwa okuphelele.

Njengamanje, uYangyang udluliselwe eWadi 6 yoMnyango Wokufakelwa Kwe-Bone Marrow ukuze athole ukwelashwa okwengeziwe. UDkt. Hai waseWadi 6 uthe uYangyang ubelokhu ebambisana futhi enethemba kulo lonke ukwelashwa kwakhe. Wafakelwa i-allogeneic hematopoietic stem cell (kuyise) ngoSepthemba 28. Izimo ezadalwa ozakwabo boMnyango We-Hematology zokufakelwa kwakhe i-bridging zaziswa kakhulu.

Lezi ziguli, ngaphambi kokubhaliswa esivivinyweni somtholampilo se-CD7 CAR-T, zaveza izimpawu ezahlukahlukene ezifana nokubuyela emuva ngemva kokufakelwa, ukubonakaliswa okubili kwe-T/myeloid, i-acute T-cell leukemia engapheli/engazweli, i-central nervous system leukemia, ukuphuma kwegazi ngaphakathi kobuchopho, kanye nokutheleleka kwamaphaphu. Ngemva kokuhlolwa nokwelashwa nge-CD7 CAR-T therapy, zonke zathola ukuthethelelwa okuphelele, zahlangabezana nemiphumela elindelekile.

Isikhungo sethu se-CGT sihlole ngenkuthalo emkhakheni wezokwelapha nge-CAR-T futhi saqoqa ulwazi olucebile ekuphatheni i-CRS. Kwabaningi abahlanganyeli, umphumela omubi kakhulu kwaba umkhuhlane ophezulu. "Ngingafinyelela ukuphulukiswa okuphelele, ngakho umkhuhlane awulutho! Ngifuna abantu abaningi bazi ukuthi i-BIOOCUS ingenza i-CAR-T!" kusho uYangyang waseFujian ngemuva kokukhishwa esibhedlela.